Related Experiment Video
Updated: Mar 15, 2026
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
NLRC4 suppresses melanoma tumor progression independently of inflammasome activation
Abstract:
Members of the NLR family can assemble inflammasome complexes with the adaptor protein ASC and caspase-1 that result in the activation of caspase-1 and the release of IL-1β and IL-18. Although the NLRC4 inflammasome is known to have a protective role in tumorigenesis, there is an increased appreciation for the inflammasome-independent actions of NLRC4. Here, we utilized a syngeneic subcutaneous murine model of B16F10 melanoma to explore the role of NLRC4 in tumor suppression. We found that NLRC4-deficient mice exhibited enhanced tumor growth that was independent of the inflammasome components ASC and caspase-1. Nlrc4 expression was critical for cytokine and chemokine production in tumor-associated macrophages and was necessary for the generation of protective IFN-γ-producing CD4+ and CD8+ T cells. Tumor progression was diminished when WT or caspase-1-deficient, but not NLRC4-deficient, macrophages were coinjected with B16F10 tumor cells in NLRC4-deficient mice. Finally, examination of human primary melanomas revealed the extensive presence of NLRC4+ tumor-associated macrophages. In contrast, there was a paucity of NLRC4+ tumor-associated macrophages observed in human metastatic melanoma, supporting the concept that NLRC4 expression controls tumor growth. These results reveal a critical role for NLRC4 in suppressing tumor growth in an inflammasome-independent manner.
Insights
NLRC4 protein suppresses melanoma growth by promoting immune cell activity, independent of inflammasome pathways. Loss of NLRC4 in mice led to faster tumor progression and reduced protective T cells.
Area of Science:
- Immunology
- Cancer Biology
- Molecular Biology
Background:
- NLRC4 inflammasome activation leads to IL-1β and IL-18 release.
- NLRC4 has known roles in tumorigenesis, but inflammasome-independent functions are emerging.
- The role of NLRC4 in melanoma suppression requires further investigation.
Purpose of the Study:
- To investigate the inflammasome-independent role of NLRC4 in suppressing B16F10 melanoma tumor growth.
- To determine the impact of NLRC4 deficiency on immune cell populations within the tumor microenvironment.
Main Methods:
- Utilized a syngeneic subcutaneous murine model of B16F10 melanoma.
- Compared tumor growth in NLRC4-deficient mice versus wild-type mice.
- Assessed cytokine and chemokine production in tumor-associated macrophages and T cell populations (CD4+, CD8+).
- Examined human primary and metastatic melanoma tissues for NLRC4 expression in tumor-associated macrophages.
Main Results:
- NLRC4-deficient mice showed enhanced tumor growth, independent of ASC and caspase-1.
- NLRC4 expression was crucial for cytokine/chemokine production in tumor-associated macrophages.
- NLRC4 was necessary for generating protective IFN-γ-producing CD4+ and CD8+ T cells.
- Human primary melanomas had abundant NLRC4+ macrophages, while metastatic melanomas had few.
Conclusions:
- NLRC4 plays a critical role in suppressing melanoma tumor growth through inflammasome-independent mechanisms.
- NLRC4 expression in tumor-associated macrophages is essential for anti-tumor immunity.
- NLRC4 deficiency correlates with increased tumor progression and reduced T cell responses.
